Ping Yang, CEO
The Coronavirus outbreak has severely affected global health crisis management. While the initial response has been to address the critical needs of COVID-19 patients, hidden acute and chronic implications of the outbreak could have a more profound impact across the population. To this end, DNA technologies play a significant role. It can help conquer these unprecedented challenges presented by the pandemic. The sequencing of the Coronavirus helps in the development of precise diagnostic kits, and DNA synthesis and engineering can aid the development of the vaccine. Also, DNA editing technologies can be employed in both diagnostic and treatment approaches.
That’s where Synbio Technologies comes in. As an advanced and cost-effective DNA solution provider, the company has synthesized probes used for nucleic acid detection kits, DNA and RNA for vaccine discovery, and targeting proteins for antibody discovery during the pandemic. In addition, they have also developed a silicon-based de novo antibody discovery platform, which facilitates the process of designing an antibody to any target.
The de novo antibody discovery platform combines antibody molecule computer simulation design technology with DNA manufacturing technology. As such, it allows the clients of Synbio Technologies to shorten the antibody R&D cycle. For instance, a pharma customer collaborated with Synbio Technologies for developing a PD-L1 antibody with high binding affinity. The company tackled this task of affinity evolution through its Syno® Ab algorithm. After several weeks of calculating and refining molecules, Synbio Technologies successfully obtained the in silicon “hits” and then manufactured those. Traditionally, this work would take around 1.5-2 years, but the de novo antibody discovery approach reduced it to only 4 to 6 months. “Synbio Technologies is incorporated under our belief in “Genes for Life”.
Having decades of experience in the DNA industry, we have synthesized many therapeutic antibodies, proteins, drug candidates, and drug targets,” says Dr. Ping Yang, the CEO of Synbio Technologies.
Our mission is to innovate through DNA creation and translate these innovations into our customers’ research to reduce cost, modify workflow, and ultimately improve productivity
Indeed, Synbio Technologies’s focus on DNA synthesis and computational aided bio-design have helmed several scientific discoveries and drug innovation. The company is also recognized for its comprehensive Synotype platforms that integrate cutting edge synthetic biology techniques and bioinformatic tools into an advanced biological innovation platform. This enables the company to deepen its knowledge on genotyping, characterize phenotyping, study genotyping and phenotyping correlations, and cost-effectively design and produce the novel sequence and subsequent function traits.
In addition to the impact on drug discovery and life sciences, Synbio Technologies’s DNA solutions provide many new thoughts in the synthetic biology industry too. For example, its patented technology can translate any digital information into DNA sequences to generate a DNA type watermark. It can be used to enclave the DNA watermark into DNA constructs and cell lines to generate IP protection at a DNA level. “Our mission is to innovate through DNA creation and translate these innovations into our customers’ research to reduce cost, modify workflow, and ultimately improve productivity,” says Dr. Yang.
What differentiates Synbio Technologies is its never-ending focus on better serving the scientific communities across the globe. The company performs every operation with utmost precision and care for its clients. “At Synbio Technologies, we tell ourselves to continue focusing on DNA manufacturing technologies and DNA design,” states Dr. Yang. For the future, the company believes that they can design and engineer DNA solutions into DNA constructs that will translate into better phenotypes. The company is also envisioning the improvement of protein yield and more precise diagnostic and individualized medicines. From a geographical standpoint, Synbio Technologies has planned to expand both its manufacturing facility and bio-design platforms in New Jersey.